One-on-one with Ventus Medical CEO Peter Wyles
Rest easy, the FDA approval process for medical devices isn’t always a nightmare.
Ventus Medical Inc. has won three FDA approvals in just a few years for its therapy for obstructive sleep apnea, or OSA. Now with solid results from a 250-patient trial in hand, President and CEO Peter Wyles is aiming not to convince the FDA to approve the therapy but doctors to prescribe it.
Ventus, backed by De Novo Ventures, Mohr Davidow Ventures and Johnson & Johnson Development Corp., has raised $62 million to date and over the past several months has built a commercial sales force that is selling the device, branded as Provent. In all, the Belmont company has 37 full-time employees, with a few sales positions still open.